Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 28:17:100319.
doi: 10.1016/j.lrr.2022.100319. eCollection 2022.

Current and emerging monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies in treatment of lymphoma

Suheil Albert Atallah-Yunes  1 , Michael J Robertson  2
Affiliations

Current and emerging monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies in treatment of lymphoma

Suheil Albert Atallah-Yunes et al. Leuk Res Rep. .

Abstract

The improvement in outcomes seen with the introduction of rituximab, a CD20 monoclonal antibody in combination with chemotherapy or as a single agent in the treatment of indolent non-Hodgkin lymphomas has paved the way for development of various forms of monoclonal antibodies that act in different ways against non-Hodgkin lymphoma tumor cells. These could directly target a single surface antigen resulting in various ways of tumor cells toxicity and killing. Other forms of monoclonal antibodies include antibody-drug conjugates and bispecific antibodies. The role of therapeutic monoclonal antibodies in the treatment of lymphoma will be reviewed, highlighting their mode of action, clinical efficacy, and side effects.

Keywords: Antibody drug conjugates; Bispecific antibodies; Immunotherapy; Lymphoma; Monoclonal antibodies.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by

References

    1. Maloney D.G., Liles T.M., Czerwinski D.K., Waldichuk C., Rosenberg J., Grillo-Lopez A., et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood. 1994;84(8):2457–2466. - PubMed
    1. Mohammed R., Milne A., Kayani K., Ojha U. How the discovery of rituximab impacted the treatment of B-cell non-Hodgkin's lymphomas. J. Blood Med. 2019;10:71–84. - PMC - PubMed
    1. Salles G., Barrett M., Foà R., Maurer J., O'Brien S., Valente N., et al. Rituximab in B-Cell Hematologic Malignancies: a Review of 20 Years of Clinical Experience. Adv. Ther. 2017;34(10):2232–2273. - PMC - PubMed
    1. Assi R., Masri N., Abou Dalle I., El-Cheikh J., Ghanem H., Bazarbachi AJCHI. Polatuzumab Vedotin: current Role and Future Applications in the Treatment of Patients with Diffuse Large B-Cell Lymphoma. Clin. Hematol. Int. 2021;3(1):21–26. - PMC - PubMed
    1. Lejeune M., Köse M.C., Duray E., Einsele H., Beguin Y., JJFiI Caers. Bispecific, T-cell-recruiting antibodies in B-cell malignancies. Front. Immunol. 2020;11:762. - PMC - PubMed

LinkOut - more resources